Baxter International, the U.S. maker of blood products and intravenous drugs, agreed to buy Swedish kidney-dialysis competitor Gambro AB for $2.8 billion to expand its dialysis-equipment business.
Baxter to buy Gambro for $2.8 billion to boost dialysis
December 4, 2012
This article requires free registration
This article requires free registration to Law.com. Please sign in or register to read the full text.